CarsGen-B Showcases Clinical Data for CT0596 and CT1190B at EHA 2026 Congress

Stock News

Jun 15

CarsGen-B (HKEX: 02171) has announced that research findings for two of its allogeneic CAR-T cell therapies were presented in poster sessions at the 2026 European Hematology Association (EHA) Annual Congress.

The results for CT0596, an off-the-shelf CAR-T product targeting BCMA for treating relapsed/refractory multiple myeloma and plasma cell leukemia, were displayed. Additionally, data for CT1190B, a universal CAR-T therapy targeting CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma, were also presented.

The updated findings for CT0596 were showcased on June 12, 2026, under the title "First-in-Human Study of CT0596, an allogeneic BCMA CAR T in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia: Safety, Efficacy, and Pharmacokinetic at Recommended Dose."

The latest results for CT1190B were presented on June 13, 2026, with the poster titled "First in Human Study of CT1190B, an Allogeneic Anti-CD19/CD20 CAR T-cell therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1128321434"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128321434\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128321434?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128321434","market":"hk","top_or_hot":-1,"title":"CarsGen-B Showcases Clinical Data for CT0596 and CT1190B at EHA 2026 Congress","media":"Stock News","content":"<p><b>CarsGen-B</b> (<b>HKEX: 02171</b>) has announced that research findings for two of its allogeneic CAR-T cell therapies were presented in poster sessions at the 2026 European Hematology Association (EHA) Annual Congress.<br><br>The results for CT0596, an off-the-shelf CAR-T product targeting BCMA for treating relapsed/refractory multiple myeloma and plasma cell leukemia, were displayed. Additionally, data for CT1190B, a universal CAR-T therapy targeting CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma, were also presented.<br><br>The updated findings for CT0596 were showcased on June 12, 2026, under the title \"First-in-Human Study of CT0596, an allogeneic BCMA CAR T in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia: Safety, Efficacy, and Pharmacokinetic at Recommended Dose.\"<br><br>The latest results for CT1190B were presented on June 13, 2026, with the poster titled \"First in Human Study of CT1190B, an Allogeneic Anti-CD19/CD20 CAR T-cell therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CarsGen-B Showcases Clinical Data for CT0596 and CT1190B at EHA 2026 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCarsGen-B Showcases Clinical Data for CT0596 and CT1190B at EHA 2026 Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-15 08:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CarsGen-B</b> (<b>HKEX: 02171</b>) has announced that research findings for two of its allogeneic CAR-T cell therapies were presented in poster sessions at the 2026 European Hematology Association (EHA) Annual Congress.<br><br>The results for CT0596, an off-the-shelf CAR-T product targeting BCMA for treating relapsed/refractory multiple myeloma and plasma cell leukemia, were displayed. Additionally, data for CT1190B, a universal CAR-T therapy targeting CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma, were also presented.<br><br>The updated findings for CT0596 were showcased on June 12, 2026, under the title \"First-in-Human Study of CT0596, an allogeneic BCMA CAR T in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia: Safety, Efficacy, and Pharmacokinetic at Recommended Dose.\"<br><br>The latest results for CT1190B were presented on June 13, 2026, with the poster titled \"First in Human Study of CT1190B, an Allogeneic Anti-CD19/CD20 CAR T-cell therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"","article_id":"1128321434","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128321434","pubTimestamp":1781482585,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CarsGen-B (HKEX: 02171) has announced that research findings for two of its allogeneic CAR-T cell therapies were presented in poster sessions at the 2026 European Hematology Association (EHA) Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","BK1161":"生物科技","02171":"科济药业-B","BK1574":"生物医药B类股","BK1585":"昨日强势股"},"translate_title":"科济康-B在EHA 2026大会上展示CT0596和CT1190B的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CarsGen-B (HKEX: 02171) has announced that research findings for two of its allogeneic CAR-T cell therapies were presented in poster sessions at the 2026 European Hematology Association (EHA) Annual Congress.The results for CT0596, an off-the-shelf CAR-T product targeting BCMA for treating relapsed/refractory multiple myeloma and plasma cell leukemia, were displayed. Additionally, data for CT1190B, a universal CAR-T therapy targeting CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma, were also presented.The updated findings for CT0596 were showcased on June 12, 2026, under the title \"First-in-Human Study of CT0596, an allogeneic BCMA CAR T in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia: Safety, Efficacy, and Pharmacokinetic at Recommended Dose.\"The latest results for CT1190B were presented on June 13, 2026, with the poster titled \"First in Human Study of CT1190B, an Allogeneic Anti-CD19/CD20 CAR T-cell therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}